Genitourinary Cancers | Specialty

ESMO 2019: Dr. Choueiri Discusses Novel Treatment Strategies in GU Cancers

September 29th 2019

ESMO 2019: Dr. Hamid Discusses Exciting Immunotherapy Data in Melanoma

September 29th 2019

ESMO 2019: Dr. Ramalingam Discusses Confirmatory Data in Advanced NSCLC

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 3

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 2

September 29th 2019

OncLive News Network On Location: ESMO 2019 Day 1

September 29th 2019

Enfortumab Vedotin Plus Pembrolizumab Shows Promise in Urothelial Cancer

September 28th 2019

More than 70% of patients with cisplatin-ineligible locally advanced urothelial cancer had objective responses to the investigational antibody-drug conjugate enfortumab vedotin plus pembrolizumab (Keytruda).

Sacituzumab Govitecan Active in Heavily Pretreated Metastatic Urothelial Cancer

September 28th 2019

Sacituzumab govitecan demonstrated clinical activity with an overall response rate of 29% in patients with heavily pretreated metastatic urothelial carcinoma.

Telaglenastat Plus Everolimus Emerges as Novel Approach in Metastatic RCC

September 28th 2019

Adding the investigational glutaminase inhibitor telaglenastat to everolimus extends progression-free survival compared with everolimus alone in patients with heavily pretreated advanced renal cell carcinoma.

EU Panel Backs Avelumab/Axitinib Combo for Frontline RCC

September 20th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion to recommend approval of the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.

Dr. Jonasch on Utilizing the Tumor Microenvironment and Epigenetics as Biomarkers in RCC

September 19th 2019

Eric Jonasch, MD, on how understanding features within the tumor microenvironment and mutated epigenetic modifying genes may provide insight on prognosis or treatment strategies in renal cell carcinoma.

Dr. Henske Discusses a Pathway Deficiency in Chromophobe RCC

September 18th 2019

Elizabeth Petri Henske, MD, director of the Center for LAM Research and Clinical Care, co-director of the Pulmonary Genetics Center at Brigham and Women’s Hospital, and professor at Harvard Medical School, discusses a newly discovered pathway in chromophobe renal cell carcinoma.

Choueiri Pushes for Discussion and Collaboration in Kidney Cancer

September 17th 2019

Toni Choueiri, MD, discusses the rationale behind the Kidney Cancer Research Summit and recent advances in the renal cell carcinoma landscape.

FDA Grants Enfortumab Vedotin Priority Review for Urothelial Cancer

September 16th 2019

The FDA has granted a priority review designation to a biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic setting.

Dr. McGregor on Choosing Combo Regimens in Advanced RCC

September 16th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses how to choose between combination treatments in advanced renal cell carcinoma.

Dr. Hammers on Challenges With CAR T-Cell Therapy in RCC

September 16th 2019

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.

Dr. Choueiri on Subsequent Combo Therapy After PD-1/PD-L1 Blockade in RCC

September 11th 2019

Toni Choueiri, MD, discusses what therapy to give patients with renal cell carcinoma after they have received a PD-1/PD-L1 blockade.

Updated OS Data Reported With Tivozanib in Highly Refractory Metastatic RCC

September 10th 2019

Results from the second prespecified analysis of the TIVO-3 trial showed a hazard ratio for overall survival of 0.99 for tivozanib compared with sorafenib in patients with highly refractory metastatic renal cell carcinoma.

Dr. Gupta on Enzalutamide/Chemo Combo in Metastatic Bladder Cancer

September 10th 2019

Shilpa Gupta, MD, associate professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the results of the phase I/Ib trial investigating the use of frontline enzalutamide, gemcitabine and cisplatin in metastatic bladder cancer.

Novel Immunotherapy Combos Shake Up Bladder Cancer Paradigm

September 4th 2019

Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.